Every drug asset,
with the evidence graded.

A due-diligence terminal that grades the evidence behind every drug asset: trial design, size, endpoints and blinding, with the rubric published and the reasoning shown. Three exhibits below, from real pages.

Exhibit A

The company page

Share price, with key events markedOpen Abivax ↗

Share price · ABVX

$92.88

Jan 2025 to 2 Oct 2026 · close as of 2026-10-02 · 24h delayed · vol 644K (0.5x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Exhibit B

The asset page

Obefazimod, the drug behind marker 1Open obefazimod ↗

Reliablesignal

Evidence outlook · lead readout

ABTECT - Maintenance (NCT05535946) · Ulcerative Colitis

The completed lead evidence has the design features that historically survive confirmatory trials: randomized, controlled, and adequately powered against a prespecified clinically accepted endpoint.

ABTECT - Maintenance (NCT05535946): This trial randomized responder patients to obefazimod 25 mg, 50 mg, or placebo under triple-blind conditions, with a large sample size (over 1,100 participants enrolled across the program), and its primary endpoint was clinical remission, a hard, disease-defining measure of ulcerative colitis activity. The comparison clearly favored obefazimod over placebo with a large effect size and high statistical significance, meeting all the elements needed for strong evidence: real randomization, blinding, an adequately sized placebo control, a hard clinical endpoint, and a statistically significant favorable result.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Also in development:Crohn's Disease · Phase 2

How the evidence outlook works ↗

Featured trials

The studies most instrumental to this drug's clinical progression, individually graded on design and result.

investigationalFeatured evidence · 3

Trial	Phase	Endpoint	Key result	Signal	Source
ABTECT-1 NCT05507203 · Ulcerative Colitis The trial was randomized, blinded, and placebo-controlled with a hard clinical/endoscopic primary endpoint (clinical remission), and both the 25 mg and 50 mg doses produced significantly higher remission rates than placebo (23.8% and 21.7% vs 2.5%, both P<0.0001). Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence. Registry: NCT05507203	3	Proportion of subjects who achieve clinical remission per Modified Mayo Score at week 8 (8 weeks) 2025-06-24	ABTECT-1 (NCT05507203), clinical remission at Week 8: placebo 2.5% (4/158), 25 mg 23.8% (38/160, p<0.0001), 50 mg 21.7% (69/318, p<0.0001; placebo-adjusted +19.3%)	Reliable signal	link ↗

View 2 more trials

ABTECT-2 NCT05507216 · Ulcerative Colitis The trial was randomized, blinded, and placebo-controlled with a hard clinical/endoscopic primary endpoint, but the result was mixed: the 50 mg dose significantly beat placebo (19.8% vs 6.3%, P=0.0001) while the 25 mg dose did not (11.3% vs 6.3%, P=0.1034), so the trial did not cleanly confirm a benefit across doses. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence. Registry: NCT05507216	3	Proportion of subjects who achieve clinical remission per Modified Mayo Score at week 8 (8 weeks) 2025-06-24	ABTECT-2 (NCT05507216), clinical remission at Week 8: placebo 6.3% (10/159), 25 mg 11.3% (18/159, p=0.1034, not significant), 50 mg 19.8% (63/318, p=0.0001; placebo-adjusted +13.4%)	Partial signal	link ↗
ABTECT - Maintenance NCT05535946 · Ulcerative Colitis This trial randomized responder patients to obefazimod 25 mg, 50 mg, or placebo under triple-blind conditions, with a large sample size (over 1,100 participants enrolled across the program), and its primary endpoint was clinical remission, a hard, disease-defining measure of ulcerative colitis activity. The comparison clearly favored obefazimod over placebo with a large effect size and high statistical significance, meeting all the elements needed for strong evidence: real randomization, blinding, an adequately sized placebo control, a hard clinical endpoint, and a statistically significant favorable result. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence. Registry: NCT05535946	3	Rate of subjects in clinical remission at Week 44 2026-04-28	ABTECT maintenance, clinical remission at Week 44: placebo 10.4% (20), 25 mg 50.8% (98; placebo-adjusted +39.3%), 50 mg 51.3% (100; placebo-adjusted +40.3%), p<0.0001	Reliable signal	link ↗

Trial designThe signal grades the trial's design, size, endpoint and blinding.
The reasoning is shownEvery graded trial carries its rationale.

Exhibit C

The comparison tool

Obefazimod vs adalimumab, ulcerative colitisOpen the comparison ↗

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Coverage. Obefazimod: 12 of 12 rows · Adalimumab: 12 of 12 rows. Blank cells mean the asset's registered results never reported the endpoint.

Reported metric	Obefazimod Rows use multiple source trials	Adalimumab Rows use multiple source trials
Clinical Remission responder rate · % of participants	21.7% vs 2.5% placebo @ 8wk50 mg^a,b,c NCT05507203 · Phase 3 · sponsor-reported, not registry data show 1 more dose 23.8% vs 2.5% placebo @ 8wk25 mg NCT05507203 · Phase 3 · sponsor-reported, not registry data	18.5% (n=130) vs 9.2% (n=130) placebo @ 8wk160/80/40^a,b,c NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 1 more dose 10% (n=130) vs 9.2% (n=130) placebo @ 8wk80/40 NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Clinical Remission responder rate · % of participants No placebo or comparator arm	54.8% (n=217) @ 48wk*50mg^d,b,c NCT04023396 · Phase 2 · registry result, not featured evidence · converted to % from 119 Participants as posted	61.2% (n=585) @ 48wk40 mg EOW/EW^d,b,c NCT00573794 · Phase 3 · registry result, not featured evidence · monotherapy
Clinical Response responder rate · % of participants	58.7% (n=63) vs 34.4% (n=64) placebo @ 8wk50 mg^a,d,b,c NCT03760003 · Phase 2 · registry result, not featured evidence show 2 more doses 62.3% (n=61) vs 34.4% (n=64) placebo @ 8wk25 mg NCT03760003 · Phase 2 · registry result, not featured evidence 50% (n=64) vs 34.4% (n=64) placebo @ 8wk100 mg NCT03760003 · Phase 2 · registry result, not featured evidence	54.6% (n=130) vs 44.6% (n=130) placebo @ 8wk160/80/40^a,d,b,c NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 1 more dose 51.5% (n=130) vs 44.6% (n=130) placebo @ 8wk80/40 NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Mucosal Healing event count · % of participants	1.6% (n=63) vs 3.1% (n=64) placebo @ 8wk50 mg^a,d,b,c NCT03760003 · Phase 2 · registry result, not featured evidence show 2 more doses 0% (n=61) vs 3.1% (n=64) placebo @ 8wk25 mg NCT03760003 · Phase 2 · registry result, not featured evidence 0% (n=64) vs 3.1% (n=64) placebo @ 8wk100 mg NCT03760003 · Phase 2 · registry result, not featured evidence	46.9% (n=130) vs 41.5% (n=130) placebo @ 8wk160/80/40^a,d,b,c NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 1 more dose 37.7% (n=130) vs 41.5% (n=130) placebo @ 8wk80/40 NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Partial Mayo absolute change · score No placebo or comparator arm	-2.2 score^d,b,c,e NCT03368118 · Phase 2 · registry result, not featured evidence	-2 score @ 388wk40 mg EOW/EW^d,b,c,e NCT00573794 · Phase 3 · registry result, not featured evidence · monotherapy
Rectal Bleeding Subscore 0 1 event count · % of participants	72.1% (n=61) vs 51.6% (n=64) placebo @ 8wk50 mg^a,d,b,c NCT03760003 · Phase 2 · registry result, not featured evidence show 2 more doses 76.7% (n=60) vs 51.6% (n=64) placebo @ 8wk25 mg NCT03760003 · Phase 2 · registry result, not featured evidence 76.2% (n=63) vs 51.6% (n=64) placebo @ 8wk100 mg NCT03760003 · Phase 2 · registry result, not featured evidence	77.7% (n=130) vs 66.2% (n=130) placebo @ 8wk160/80/40^a,d,b,c NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 1 more dose 70% (n=130) vs 66.2% (n=130) placebo @ 8wk80/40 NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
SF-36 MCS absolute change · score No placebo or comparator arm	6.38 score^d,b,c,e NCT03368118 · Phase 2 · registry result, not featured evidence	-7.3 score @ 388wk40 mg EOW/EW^d,b,c,e NCT00573794 · Phase 3 · registry result, not featured evidence · monotherapy
SF-36 PCS absolute change · score No placebo or comparator arm	4.82 score^d,b,c,e NCT03368118 · Phase 2 · registry result, not featured evidence	8.4 score @ 388wk40 mg EOW/EW^d,b,c,e NCT00573794 · Phase 3 · registry result, not featured evidence · monotherapy
Dropout rate	24.4%50mg^f NCT04023396 · Phase 2 · registry result, not featured evidence show 9 more results 50% NCT03368118 · Phase 2 · registry result, not featured evidence 15.9%50 mg NCT03760003 · Phase 2 · registry result, not featured evidence —50 mg NCT03760003 · Phase 2 · registry result, not featured evidence 7.9%25 mg NCT03760003 · Phase 2 · registry result, not featured evidence —25mg NCT03760003 · Phase 2 · registry result, not featured evidence 15.6%100 mg NCT03760003 · Phase 2 · registry result, not featured evidence —100mg NCT03760003 · Phase 2 · registry result, not featured evidence —ABX464 NCT03093259 · Phase 2 · registry result, not featured evidence 8.7%ABX464 Treatment Arm NCT03093259 · Phase 2 · registry result, not featured evidence	6.9%160/80/40^g NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 18 more results 9.2%80/40 NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 37.6%160/80/40 NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3 —Adalimumab Group - Double-Blind Pe NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 52.5% NCT02632175 · Phase 3 · registry result, not featured evidence · monotherapy —high dose NCT02065557 · Phase 3 · registry result, not featured evidence · combination · Ulcerative Colitis · phase 3 —open-label high dose NCT02065557 · Phase 3 · registry result, not featured evidence · combination · Ulcerative Colitis · phase 3 —standard dose NCT02065557 · Phase 3 · registry result, not featured evidence · combination · Ulcerative Colitis · phase 3 —high dose NCT02065557 · Phase 3 · registry result, not featured evidence · combination · Ulcerative Colitis · phase 3 —standard dose NCT02065557 · Phase 3 · registry result, not featured evidence · combination · Ulcerative Colitis · phase 3 10.3%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · registry result, not featured evidence · combination · Ulcerative Colitis · phase 3 12.4%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · registry result, not featured evidence · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · registry result, not featured evidence · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · registry result, not featured evidence · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study): TDM Regi NCT02065622 · Phase 3 · registry result, not featured evidence · monotherapy · Ulcerative Colitis · phase 3 56.4%40 mg EOW/EW NCT00573794 · Phase 3 · registry result, not featured evidence · monotherapy 23.8% NCT01550965 · Phase 3 · registry result, not featured evidence · monotherapy · Ulcerative Colitis · phase 3 34.1%160 mg/80 mg NCT00853099 · Phase 3 · registry result, not featured evidence · monotherapy · Ulcerative Colitis · phase 3 33.3%80 mg/40 mg NCT00853099 · Phase 3 · registry result, not featured evidence · monotherapy · Ulcerative Colitis · phase 3
Discontinued due to AEs	7.4%50mg^f NCT04023396 · Phase 2 · registry result, not featured evidence show 9 more results — NCT03368118 · Phase 2 · registry result, not featured evidence —50 mg NCT03760003 · Phase 2 · registry result, not featured evidence —50 mg NCT03760003 · Phase 2 · registry result, not featured evidence —25 mg NCT03760003 · Phase 2 · registry result, not featured evidence —25mg NCT03760003 · Phase 2 · registry result, not featured evidence —100 mg NCT03760003 · Phase 2 · registry result, not featured evidence —100mg NCT03760003 · Phase 2 · registry result, not featured evidence —ABX464 NCT03093259 · Phase 2 · registry result, not featured evidence 4.3%ABX464 Treatment Arm NCT03093259 · Phase 2 · registry result, not featured evidence	3.1%160/80/40^g NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 18 more results 4.6%80/40 NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 5%160/80/40 NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3 —Adalimumab Group - Double-Blind Pe NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 — NCT02632175 · Phase 3 · registry result, not featured evidence · monotherapy —high dose NCT02065557 · Phase 3 · registry result, not featured evidence · combination · Ulcerative Colitis · phase 3 —open-label high dose NCT02065557 · Phase 3 · registry result, not featured evidence · combination · Ulcerative Colitis · phase 3 —standard dose NCT02065557 · Phase 3 · registry result, not featured evidence · combination · Ulcerative Colitis · phase 3 —high dose NCT02065557 · Phase 3 · registry result, not featured evidence · combination · Ulcerative Colitis · phase 3 —standard dose NCT02065557 · Phase 3 · registry result, not featured evidence · combination · Ulcerative Colitis · phase 3 3.3%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · registry result, not featured evidence · combination · Ulcerative Colitis · phase 3 3.4%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · registry result, not featured evidence · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · registry result, not featured evidence · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · registry result, not featured evidence · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study): TDM Regi NCT02065622 · Phase 3 · registry result, not featured evidence · monotherapy · Ulcerative Colitis · phase 3 13.8%40 mg EOW/EW NCT00573794 · Phase 3 · registry result, not featured evidence · monotherapy 5.6% NCT01550965 · Phase 3 · registry result, not featured evidence · monotherapy · Ulcerative Colitis · phase 3 14.3%160 mg/80 mg NCT00853099 · Phase 3 · registry result, not featured evidence · monotherapy · Ulcerative Colitis · phase 3 10.3%80 mg/40 mg NCT00853099 · Phase 3 · registry result, not featured evidence · monotherapy · Ulcerative Colitis · phase 3
Serious AEs	8.3%50mg^f NCT04023396 · Phase 2 · registry result, not featured evidence show 9 more results 13.6% NCT03368118 · Phase 2 · registry result, not featured evidence —50 mg NCT03760003 · Phase 2 · registry result, not featured evidence 6.3%50 mg NCT03760003 · Phase 2 · registry result, not featured evidence —25 mg NCT03760003 · Phase 2 · registry result, not featured evidence 1.6%25mg NCT03760003 · Phase 2 · registry result, not featured evidence —100 mg NCT03760003 · Phase 2 · registry result, not featured evidence 6.3%100mg NCT03760003 · Phase 2 · registry result, not featured evidence 0%ABX464 NCT03093259 · Phase 2 · registry result, not featured evidence —ABX464 Treatment Arm NCT03093259 · Phase 2 · registry result, not featured evidence	4%160/80/40^g NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 18 more results 3.8%80/40 NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 —160/80/40 NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3 12.1%Adalimumab Group - Double-Blind Pe NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 27.1% NCT02632175 · Phase 3 · registry result, not featured evidence · monotherapy 7.8%high dose NCT02065557 · Phase 3 · registry result, not featured evidence · combination · Ulcerative Colitis · phase 3 5.6%open-label high dose NCT02065557 · Phase 3 · registry result, not featured evidence · combination · Ulcerative Colitis · phase 3 15.6%standard dose NCT02065557 · Phase 3 · registry result, not featured evidence · combination · Ulcerative Colitis · phase 3 13.9%high dose NCT02065557 · Phase 3 · registry result, not featured evidence · combination · Ulcerative Colitis · phase 3 15.2%standard dose NCT02065557 · Phase 3 · registry result, not featured evidence · combination · Ulcerative Colitis · phase 3 3.8%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · registry result, not featured evidence · combination · Ulcerative Colitis · phase 3 5%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · registry result, not featured evidence · combination · Ulcerative Colitis · phase 3 12.6%Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · registry result, not featured evidence · combination · Ulcerative Colitis · phase 3 12.8%Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · registry result, not featured evidence · combination · Ulcerative Colitis · phase 3 9.9%Maintenance (Main Study): TDM Regi NCT02065622 · Phase 3 · registry result, not featured evidence · monotherapy · Ulcerative Colitis · phase 3 26.7%40 mg EOW/EW NCT00573794 · Phase 3 · registry result, not featured evidence · monotherapy 14.5% NCT01550965 · Phase 3 · registry result, not featured evidence · monotherapy · Ulcerative Colitis · phase 3 11.1%160 mg/80 mg NCT00853099 · Phase 3 · registry result, not featured evidence · monotherapy · Ulcerative Colitis · phase 3 16.1%80 mg/40 mg NCT00853099 · Phase 3 · registry result, not featured evidence · monotherapy · Ulcerative Colitis · phase 3
Most frequent reported AEs	50mg^f covid-19 14.3% headache 11.5% colitis ulcerative 7.8% NCT04023396 · Phase 2 · registry result, not featured evidence show 5 more results colitis ulcerative 31.8% abdominal pain 22.7% nasopharyngitis 22.7% NCT03368118 · Phase 2 · registry result, not featured evidence 50 mg headache 30.2% (placebo 7.8%) nausea 6.3% (placebo 6.3%) abdominal pain upper 4.8% (placebo 0%) NCT03760003 · Phase 2 · registry result, not featured evidence 25mg headache 21% (placebo 7.8%) nausea 8.1% (placebo 6.3%) abdominal pain upper 4.8% (placebo 0%) NCT03760003 · Phase 2 · registry result, not featured evidence 100mg headache 42.2% (placebo 7.8%) nausea 14.1% (placebo 6.3%) arthralgia 7.8% (placebo 4.7%) NCT03760003 · Phase 2 · registry result, not featured evidence abdominal pain 17.4% (placebo 11.1%) headache 17.4% (placebo 0%) abdominal pain upper 13% (placebo 0%) NCT03093259 · Phase 2 · registry result, not featured evidence	160/80/40^g colitis ulcerative 4% (placebo 3.6%) fatigue 4% (placebo 2.2%) headache 3.1% (placebo 7.2%) NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 17 more results 80/40 headache 6.9% (placebo 7.2%) colitis ulcerative 5.4% (placebo 3.6%) nasopharyngitis 4.6% (placebo 1.8%) NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 nasopharyngitis 17.5% (placebo 10.4%) colitis ulcerative 16.3% (placebo 22.3%) headache 8.6% (placebo 14.2%) NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 colitis ulcerative 33.9% upper respiratory tract infection 27.1% nasopharyngitis 22% NCT02632175 · Phase 3 · registry result, not featured evidence · monotherapy high dose headache 9.8% (placebo 16.7%) anaemia 5.9% (placebo 8.3%) nausea 5.9% (placebo 0%) NCT02065557 · Phase 3 · registry result, not featured evidence · combination · Ulcerative Colitis · phase 3 open-label high dose headache 22.2% (placebo 16.7%) abdominal pain 11.1% (placebo 8.3%) oropharyngeal pain 11.1% (placebo 0%) NCT02065557 · Phase 3 · registry result, not featured evidence · combination · Ulcerative Colitis · phase 3 standard dose headache 12.5% (placebo 16.7%) colitis ulcerative 6.3% (placebo 16.7%) nasopharyngitis 6.3% (placebo 8.3%) NCT02065557 · Phase 3 · registry result, not featured evidence · combination · Ulcerative Colitis · phase 3 high dose colitis ulcerative 11.1% (placebo 16.7%) nasopharyngitis 11.1% (placebo 8.3%) upper respiratory tract infection 11.1% (placebo 16.7%) NCT02065557 · Phase 3 · registry result, not featured evidence · combination · Ulcerative Colitis · phase 3 standard dose headache 18.2% (placebo 16.7%) c-reactive protein increased 9.1% (placebo 0%) colitis ulcerative 9.1% (placebo 16.7%) NCT02065557 · Phase 3 · registry result, not featured evidence · combination · Ulcerative Colitis · phase 3 headache 8.4% nasopharyngitis 5.1% arthralgia 3.1% NCT02065622 · Phase 3 · registry result, not featured evidence · combination · Ulcerative Colitis · phase 3 headache 6.1% colitis ulcerative 5.3% nasopharyngitis 4.2% NCT02065622 · Phase 3 · registry result, not featured evidence · combination · Ulcerative Colitis · phase 3 colitis ulcerative 13.4% nasopharyngitis 13.1% arthralgia 6.6% NCT02065622 · Phase 3 · registry result, not featured evidence · combination · Ulcerative Colitis · phase 3 colitis ulcerative 17.4% nasopharyngitis 13.6% arthralgia 6.7% NCT02065622 · Phase 3 · registry result, not featured evidence · combination · Ulcerative Colitis · phase 3 colitis ulcerative 15.2% nasopharyngitis 7.3% upper respiratory tract infection 6% NCT02065622 · Phase 3 · registry result, not featured evidence · monotherapy · Ulcerative Colitis · phase 3 40 mg EOW/EW colitis ulcerative 30.4% viral upper respiratory tract infection 19.4% arthralgia 10.5% NCT00573794 · Phase 3 · registry result, not featured evidence · monotherapy colitis ulcerative 13.2% headache 13% nasopharyngitis 8% NCT01550965 · Phase 3 · registry result, not featured evidence · monotherapy · Ulcerative Colitis · phase 3 160 mg/80 mg nasopharyngitis 33.3% (placebo 21.9%) iron deficiency anaemia 8.9% (placebo 7.3%) headache 7.8% (placebo 6.3%) NCT00853099 · Phase 3 · registry result, not featured evidence · monotherapy · Ulcerative Colitis · phase 3 80 mg/40 mg nasopharyngitis 21.8% (placebo 21.9%) injection site reaction 8% (placebo 2.1%) dental caries 6.9% (placebo 5.2%) NCT00853099 · Phase 3 · registry result, not featured evidence · monotherapy · Ulcerative Colitis · phase 3

Notes

aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
bPopulation comparability has not been reviewed for both studies.
cTreatment context has not been resolved for both arms.
dTrial phases differ: Phase 3 versus Phase 2.
eThe assessment timepoint is not available for both results.
fPopulation comparability has not been reviewed for these studies.
gPopulation comparability has not been reviewed for 2 of these studies.

Reported by one asset only

Obefazimod 72 · Adalimumab 52

Endpoints only one of the selected assets measured, so there is nothing to compare them against. Listed so the record is complete.

Obefazimod

Clinical Response 81.6% (n=217) @ 48wk50mg

responder rate · % of participants

No placebo or comparator arm

NCT04023396 · Phase 2 · registry result, not featured evidence

show 2 more results

72.8% (n=217) @ 96wk50mg

NCT04023396 · Phase 2 · registry result, not featured evidence

50% (n=22) @ 208wk

NCT03368118 · Phase 2 · registry result, not featured evidence

Endoscopic Improvement 61.3% (n=217) @ 48wk50mg

event count · % of participants

No placebo or comparator arm

NCT04023396 · Phase 2 · registry result, not featured evidence

show 2 more results

59% (n=217) @ 96wk50mg

NCT04023396 · Phase 2 · registry result, not featured evidence

40.9% (n=22) @ 208wk

NCT03368118 · Phase 2 · registry result, not featured evidence

Endoscopic Remission 33.2% (n=217) @ 48wk50mg

responder rate · % of participants

No placebo or comparator arm

NCT04023396 · Phase 2 · registry result, not featured evidence

show 2 more results

35.9% (n=217) @ 96wk50mg

NCT04023396 · Phase 2 · registry result, not featured evidence

27.3% (n=22) @ 208wk

NCT03368118 · Phase 2 · registry result, not featured evidence

Sustained Endoscopic Improvement 24.4% (n=217) @ 48wk50mg

event count · % of participants

No placebo or comparator arm

Sustained endoscopic improvement at Week 48

NCT04023396 · Phase 2 · registry result, not featured evidence

Sustained Endoscopic Remission 6% (n=217) @ 48wk50mg

responder rate · % of participants

No placebo or comparator arm

Sustained endoscopic remission at Week 48

NCT04023396 · Phase 2 · registry result, not featured evidence

Sustained Endoscopic Improvement 23% (n=217) @ 96wk50mg

event count · % of participants

No placebo or comparator arm

Sustained endoscopic improvement at Week 96

NCT04023396 · Phase 2 · registry result, not featured evidence

Sustained Endoscopic Remission 5.1% (n=217) @ 96wk50mg

responder rate · % of participants

No placebo or comparator arm

Sustained endoscopic remission at Week 96

NCT04023396 · Phase 2 · registry result, not featured evidence

MMS 1.8 score @ 48wk50mg

absolute change · score

No placebo or comparator arm

MMS Week 48

NCT04023396 · Phase 2 · registry result, not featured evidence

MMS 1.5 score @ 96wk50mg

absolute change · score

No placebo or comparator arm

MMS Week 96

NCT04023396 · Phase 2 · registry result, not featured evidence

Partial Mayo 1.4 score @ 4wk50mg

absolute change · score

No placebo or comparator arm

pMMS Week 4

NCT04023396 · Phase 2 · registry result, not featured evidence

Partial Mayo 1.4 score @ 8wk50mg

absolute change · score

No placebo or comparator arm

pMMS Week 8

NCT04023396 · Phase 2 · registry result, not featured evidence

Partial Mayo 1.3 score @ 12wk50mg

absolute change · score

No placebo or comparator arm

pMMS Week 12

NCT04023396 · Phase 2 · registry result, not featured evidence

+ 60 further endpoints in the CSV export.

Adalimumab

Physician Global Assessment Subscore 0 1 60% (n=130) vs 46.9% (n=130) placebo @ 8wk160/80/40

event count · % of participants

NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3

show 1 more result

53.8% (n=130) vs 46.9% (n=130) placebo @ 8wk80/40

NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3

Stool Frequency Subscore 0 1 48.5% (n=130) vs 37.7% (n=130) placebo @ 8wk160/80/40

event count · % of participants

NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3

show 1 more result

36.2% (n=130) vs 37.7% (n=130) placebo @ 8wk80/40

NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3

IBDQ 42.2% (n=90) vs 39.6% (n=96) placebo @ 8wk160 mg/80 mg

responder rate · % of participants

NCT00853099 · Phase 3 · registry result, not featured evidence · monotherapy · Ulcerative Colitis · phase 3

show 9 more results

28.9% (n=90) vs 21.9% (n=96) placebo @ 32wk160 mg/80 mg

NCT00853099 · Phase 3 · registry result, not featured evidence · monotherapy · Ulcerative Colitis · phase 3

21.1% (n=90) vs 12.5% (n=96) placebo @ 52wk160 mg/80 mg

NCT00853099 · Phase 3 · registry result, not featured evidence · monotherapy · Ulcerative Colitis · phase 3

48.3% (n=87) vs 39.6% (n=96) placebo @ 8wk80 mg/40 mg

NCT00853099 · Phase 3 · registry result, not featured evidence · monotherapy · Ulcerative Colitis · phase 3

33.3% (n=87) vs 21.9% (n=96) placebo @ 32wk80 mg/40 mg

NCT00853099 · Phase 3 · registry result, not featured evidence · monotherapy · Ulcerative Colitis · phase 3

29.9% (n=87) vs 12.5% (n=96) placebo @ 52wk80 mg/40 mg

NCT00853099 · Phase 3 · registry result, not featured evidence · monotherapy · Ulcerative Colitis · phase 3

60.8% (n=130) vs 57.7% (n=130) placebo @ 8wk160/80/40

NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3

53.8% (n=130) vs 57.7% (n=130) placebo @ 8wk80/40

NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3

26.2% (n=248) vs 16.3% (n=246) placebo @ 52wk160/80/40

NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3

58.1% (n=248) vs 45.5% (n=246) placebo @ 8wk160/80/40

NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3

Sustained Clinical Remission 8.5% (n=248) vs 4.1% (n=246) placebo160/80/40

responder rate · % of participants

NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3

Sustained Clinical 23.8% (n=248) vs 12.2% (n=246) placebo160/80/40

responder rate · % of participants

NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3

Mucosal Healing 44.4% (n=90) vs 30.2% (n=96) placebo @ 8wk160 mg/80 mg

responder rate · % of participants

NCT00853099 · Phase 3 · registry result, not featured evidence · monotherapy · Ulcerative Colitis · phase 3

show 7 more results

31.1% (n=90) vs 21.9% (n=96) placebo @ 32wk160 mg/80 mg

NCT00853099 · Phase 3 · registry result, not featured evidence · monotherapy · Ulcerative Colitis · phase 3

28.9% (n=90) vs 15.6% (n=96) placebo @ 52wk160 mg/80 mg

NCT00853099 · Phase 3 · registry result, not featured evidence · monotherapy · Ulcerative Colitis · phase 3

39.1% (n=87) vs 30.2% (n=96) placebo @ 8wk80 mg/40 mg

NCT00853099 · Phase 3 · registry result, not featured evidence · monotherapy · Ulcerative Colitis · phase 3

27.6% (n=87) vs 21.9% (n=96) placebo @ 32wk80 mg/40 mg

NCT00853099 · Phase 3 · registry result, not featured evidence · monotherapy · Ulcerative Colitis · phase 3

28.7% (n=87) vs 15.6% (n=96) placebo @ 52wk80 mg/40 mg

NCT00853099 · Phase 3 · registry result, not featured evidence · monotherapy · Ulcerative Colitis · phase 3

41.1% (n=248) vs 31.7% (n=246) placebo @ 8wk160/80/40

NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3

25% (n=248) vs 15.4% (n=246) placebo @ 52wk160/80/40

NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3

Sustained Mucosal Healing 18.5% (n=248) vs 10.6% (n=246) placebo160/80/40

responder rate · % of participants

NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3

Corticosteroid-free Clinical Remission 13.3% (n=150) vs 5.7% (n=140) placebo @ 52wk160/80/40

responder rate · % of participants

NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3

show 1 more result

13.3% (n=150) vs 5.7% (n=140) placebo @ 52wk160/80/40

NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3

PGA 0-1 46% (n=248) vs 37.4% (n=246) placebo @ 8wk160/80/40

responder rate · % of participants

NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3

Stool Frequency Subscore 0 1 40% (n=90) vs 32.3% (n=96) placebo @ 8wk160 mg/80 mg

responder rate · % of participants

NCT00853099 · Phase 3 · registry result, not featured evidence · monotherapy · Ulcerative Colitis · phase 3

show 6 more results

31.1% (n=90) vs 20.8% (n=96) placebo @ 32wk160 mg/80 mg

NCT00853099 · Phase 3 · registry result, not featured evidence · monotherapy · Ulcerative Colitis · phase 3

28.9% (n=90) vs 13.5% (n=96) placebo @ 52wk160 mg/80 mg

NCT00853099 · Phase 3 · registry result, not featured evidence · monotherapy · Ulcerative Colitis · phase 3

34.5% (n=87) vs 32.3% (n=96) placebo @ 8wk80 mg/40 mg

NCT00853099 · Phase 3 · registry result, not featured evidence · monotherapy · Ulcerative Colitis · phase 3

33.3% (n=87) vs 20.8% (n=96) placebo @ 32wk80 mg/40 mg

NCT00853099 · Phase 3 · registry result, not featured evidence · monotherapy · Ulcerative Colitis · phase 3

28.7% (n=87) vs 13.5% (n=96) placebo @ 52wk80 mg/40 mg

NCT00853099 · Phase 3 · registry result, not featured evidence · monotherapy · Ulcerative Colitis · phase 3

37.9% (n=248) vs 28.5% (n=246) placebo @ 8wk160/80/40

NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3

Rectal Bleeding Subscore 0 1 71.1% (n=90) vs 67.7% (n=96) placebo @ 8wk160 mg/80 mg

responder rate · % of participants

NCT00853099 · Phase 3 · registry result, not featured evidence · monotherapy · Ulcerative Colitis · phase 3

show 6 more results

43.3% (n=90) vs 28.1% (n=96) placebo @ 32wk160 mg/80 mg

NCT00853099 · Phase 3 · registry result, not featured evidence · monotherapy · Ulcerative Colitis · phase 3

34.4% (n=90) vs 22.9% (n=96) placebo @ 52wk160 mg/80 mg

NCT00853099 · Phase 3 · registry result, not featured evidence · monotherapy · Ulcerative Colitis · phase 3

80.5% (n=87) vs 67.7% (n=96) placebo @ 8wk80 mg/40 mg

NCT00853099 · Phase 3 · registry result, not featured evidence · monotherapy · Ulcerative Colitis · phase 3

40.2% (n=87) vs 28.1% (n=96) placebo @ 32wk80 mg/40 mg

NCT00853099 · Phase 3 · registry result, not featured evidence · monotherapy · Ulcerative Colitis · phase 3

32.2% (n=87) vs 22.9% (n=96) placebo @ 52wk80 mg/40 mg

NCT00853099 · Phase 3 · registry result, not featured evidence · monotherapy · Ulcerative Colitis · phase 3

70.2% (n=248) vs 58.1% (n=246) placebo @ 8wk160/80/40

NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3

Sustained Corticosteroid-free Clinical Remission 10% (n=150) vs 1.4% (n=140) placebo160/80/40

responder rate · % of participants

NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3

+ 40 further endpoints in the CSV export.

FootnotesEach caveat is marked in the cell and written out once below the table.
Source dataBoth columns come from each drug's own registry results.
Unshared endpointsEndpoints only one drug measured sit below the table.

Appendix

Where to start

Create a free account Read the rubric

Example pages, shown as they appear to Research members. Educational research only, not investment advice. Evidence quality is graded; securities never are.